Current head and neck research projects


Pawan Kumar, MS, PhD
  • Delineating the role of IL-6 in head and neck cancer progression
  • Identifying novel therapeutic targets for the treatment of head and neck cancers
  • Understanding the role of tumor-associated andothelial cells in promoting tumor metastasis
  • Identifying microRNA dysregulation and studying their role in head and neck cancer progression
Research Grants

Research Grants

Current Research Grants

Sponsor: NIH/NCI SAIC
PI: Jas Lang, PhD
Title: Frederick Cancer Genome Atlas Project (TCGA) BOA 13XS121
Period: 03/26/2013 - present
Goal: The goal of this study is to function as a Tissue Source Site (TSS) to process and provide specimens of head and neck squamous cell carcinoma and matched blood samples for the TCGA project.

Clinical Trials for Head and Neck

Phase III Randomized, Open-Label, Multicenter, Global Study of MEDI4736 Alone or in Combination With Tremelimumab vs. Standard of Care in the Treatment of First-Line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients
(OSU-15210) Maura Gillison, MD, PhD

Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
(OSU-16120) Maura Gillison, MD, PhD

Randomized, Phase III Trial of Cisplatin-Based Chemotherapy (CRT) +/- Nivolumab (ANTI-PD-1) in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (with Phase I Lead in)
(RTOG-3504) Maura Gillison, MD, PhD

Open-Label, Randomized, Two-Arm Phase III Study of Nivolumab in Combination With Ipilimumab vs. Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
(OSU-16134) Maura Gillison, MD, PhD

Open-Label, Multicenter Phase I/II Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
(OSU-16147) Maura Gillison, MD, PhD

Past Head and Neck Research Grants

 

  • Role of Tumor-Associated Endothelial Cells in Chaperoning Tumor Cells
    PI: Pawan Kumar, MS, PhD
    07/02/2014 - 06/30/2016
    NIH/NCI

  • James Rocco, MD, PhD
    07/01/2011 - 04/30/2016
    NIDCR/NCI
    R01DE022087-01

    BCL-2 as a Biomarker for Progrnosis and Therapy of Head and Neck Cancer
    The major goal of this project is to assess the role of functional Bcl2 status in predicting response to chemo-radiation therapy using the novel technique of BH3 profiling for the first time in oropharyngeal squamous cell carcinoma (OPSCC).

  • James Rocco, MD, PhD
    07/01/2011 - 04/30/2016
    NIDCR/NCI
    R01DE022087-01

    BCL-2 as a Biomarker for Progrnosis and Therapy of Head and Neck Cancer
    The major goal of this project is to assess the role of functional Bcl2 status in predicting response to chemo-radiation therapy using the novel technique of BH3 profiling for the first time in oropharyngeal squamous cell carcinoma (OPSCC).
Publications

Publications

Pawan Kumar, MS, PhD

Kumar B., Yadav A., Brown V.N., Zhao S., Cipolla M.J., Wakely P.E., Yan F., Schmitt A.C., Baiocchi R.A., Teknos T.N., Old M., and Kumar P*. "High expression of PRMT5 and Cyclin D1 predicts poor outcome in oropharyngeal squamous cell carcinoma and is inversely associated with p16 status. 2017, Oncotarget, doi: 10.18632/oncotarget.14682

Yadav A., Kumar B., Teknos T.N. and Kumar P*. Bazedoxifene enhances the anti-tumor effects of cisplatin and radiation treatment by blocking IL-6 signaling in head and neck cancer. 2016, Oncotarget, DOI: 10.18632/oncotarget.11464

McMullen K, Chalmers JJ, Lang JC, Kumar P, Jatana KR. Circulating tumor cells in head and neck cancer: A review. World J Otorhinolaryngology Head Neck Surg. 2016 Jun;2(2): 109-116

Kumar B, Cipolla M, Brown N, Kang SY, Dziegielewski PT, Durmus K, Ozer E, Old MO, Agrawal A, Carrau RL, Schuller DE, Leon M, Pan Q, Kumar P, Wood V, Burgers J, Wakely P, and Teknos TN. Surgical management of oropharyngeal squamous cell carcinoma: survival and functional outcomes. Head Neck. 2016 Apr;38 Suppl 1:E1794-802. PubMed PMID: 26694981

Kumar B, Brown N, Swanson B, Schmitt A, Old M, Ozer E, Agrawal A, Schuller D, Teknos T, Kumar P. High expression of myoferlin is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with HPV-status. Oncotarget. 2016 Apr 5;7(14):18665-77. PubMed PMID: 26919244

Choudhary M.M., France T.J., Teknos T.N. and Kumar P*. Interleukin-6 (IL-6) role in head and neck squamous cell carcinoma (HNSCC) progression. 2016, World Journal of Otorhinolaryngology - Head and Neck Surgery, In press
Our Head and Neck Research Team

Our Head and Neck Research Team

Additional Research Members

  • Edmund Mroz, PhD, Research Associate Professor
  • Bhavna Kumar, MS, Program Director
  • Gaila Sunkle, MEd, Program Manager
  • Jharna Datta, PhD, Research Associate 2-B/H
  • Bin Li PhD, Research Associate 2-B/H
  • Longzhu Piao, PhD, Research Associate 2-B/H
  • Xueqian Wang, PhD, Research Associate 2-B/H
  • Xiujie Xie, PhD, Research Associate 2-B/H
  • Arti Yadav, MS, Research Associate 1B/H
  • Anita Janssen, BS, Research Associate 1-B/H
  • Satavisha Roy, BS, Research Associate 1-B/H
  • Jason Andersen, BS, Research Assistant 1-B/H